TSXV:CLAS.H - Post by User
Post by
MartialArtson May 15, 2018 3:20pm
![](https://assets.stockhouse.com/kentico-cms/0338-00/images/Sprite.svg#id_Post_Views_Icon)
205 Views
Post# 28034593
Comparing KALY with other CBD pharmas
Comparing KALY with other CBD pharmas
Comparing CBD pharma. A first look:
Pascale Biosciences PAS (CDN PAS) - Pre-clinical only - 20.4M CAD = $15.8M USD market cap
Kalytera Therapeutics Inc.KALTF KALY - Phase 2 - $23M USD market cap
Corbus Pharmaceuticals CRBP - Phase 2 - $328M USD market cap
Zynerba Pharmaceuticals ZYNE - Phase 2 - $128M USD market cap
GW Pharmaceuticals GWPH - Phase 3 - $4B USD market cap
Keep in mind, these are not equals at all, just highlighting the fact that as KALY moves from pre-clinical to Phase1, 2, 3 its value rises and so does its take over value potential.